Evidence map›Paper›PMID 35411010›Full record

ArticleScientific reports2022

Clustering of Parkinson subtypes reveals strong influence of DRD2 polymorphism and gender.

Esther Annegret Pelzer, Sophie Stürmer, Delia-Lisa Feis, Corina Melzer, Frank Schwartz, Marcel Scharge, Carsten Eggers, Marc Tittgemeyer, Lars Timmermann

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Esther Annegret Pelzer *Max Planck Institute for Metabolism Research, Translational Neurocircuitry Group, Gleulerstrasse 50, 50931, Cologne, Germany. Esther.Pelzer@sf.mpg.de.
Sophie Stürmer *Department of Psychiatry, University Hospital Cologne, Cologne, Germany.
Delia-Lisa FeisMax Planck Institute for Metabolism Research, Translational Neurocircuitry Group, Gleulerstrasse 50, 50931, Cologne, Germany.
Corina MelzerMax Planck Institute for Metabolism Research, Translational Neurocircuitry Group, Gleulerstrasse 50, 50931, Cologne, Germany.
Frank SchwartzDepartment of Neurology, University Hospital Cologne, Cologne, Germany.
Marcel SchargeMax Planck Institute for Metabolism Research, Translational Neurocircuitry Group, Gleulerstrasse 50, 50931, Cologne, Germany.
Carsten EggersDepartment of Neurology, University Hospital Marburg, Marburg, Germany.
Marc TittgemeyerMax Planck Institute for Metabolism Research, Translational Neurocircuitry Group, Gleulerstrasse 50, 50931, Cologne, Germany.
Lars TimmermannDepartment of Neurology, University Hospital Marburg, Marburg, Germany.
Max Planck Institute for Metabolism Research · DEPhilipps University of Marburg · DEUniversity Hospital Cologne · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Most classification approaches for idiopathic Parkinson's disease subtypes primarily focus on motor and non-motor symptoms. Besides these characteristics, other features, including gender or genetic polymorphism of dopamine receptors are potential factors influencing the disease's phenotype. By utilizing a kmeans-clustering algorithm we were able to identify three subgroups mainly characterized by gender, DRD2 Taq1A (rs1800497) polymorphism-associated with changes in dopamine signaling in the brain-and disease progression. A subsequent regression analysis of these subgroups further suggests an influence of their characteristics on the daily levodopa dosage, an indicator for medication response. These findings could promote further enhancements in individualized therapies for idiopathic Parkinson's disease.

Indexed as

Parkinson DiseaseCluster AnalysisFemaleHumansLevodopaMalePolymorphism, GeneticReceptors, Dopamine D2DRD2 protein, humanLevodopaReceptors, Dopamine D2

Identifiers

PMID35411010
PMCPMC9001640
OpenAlexW4223505247

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.